{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T00:45:26Z","timestamp":1781916326326,"version":"3.54.5"},"reference-count":93,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T00:00:00Z","timestamp":1591315200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.clml.2020.05.003","type":"journal-article","created":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T21:58:20Z","timestamp":1592517500000},"page":"e782-e790","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["De Novo CD5+ Diffuse Large B-Cell Lymphoma: Biology, Mechanism, and Treatment Advances"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1265-9622","authenticated-orcid":false,"given":"Yichen","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9375-0622","authenticated-orcid":false,"given":"Wenjie","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2020.05.003_bib1","doi-asserted-by":"crossref","first-page":"5615","DOI":"10.18632\/oncotarget.3479","article-title":"Clinical and biological significance of de novo CD5+ diffuse large B-cell lymphoma in Western countries","volume":"6","author":"Xu-Monette","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.clml.2020.05.003_bib2","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1093\/annonc\/mdq057","article-title":"Clinicopathologic characteristics and treatment outcome of the addition of rituximab to chemotherapy for CD5-positive in comparison with CD5-negative diffuse large B-cell lymphoma","volume":"21","author":"Niitsu","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2020.05.003_bib3","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1093\/annonc\/mdq627","article-title":"CD5-positive diffuse large B-cell lymphoma: a retrospective study in 337 patients treated by chemotherapy with or without rituximab","volume":"22","author":"Miyazaki","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2020.05.003_bib4","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1182\/blood.V99.3.815","article-title":"De novo CD5+ diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients","volume":"99","author":"Yamaguchi","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.05.003_bib5","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1046\/j.1365-2141.1999.01513.x","article-title":"De novo CD5-positive diffuse large B-cell lymphoma: clinical characteristics and therapeutic outcome","volume":"105","author":"Yamaguchi","year":"1999","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2020.05.003_bib6","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1038\/sj.leu.2401487","article-title":"Molecular and immunological dissection of diffuse large B cell lymphoma: CD5+, and CD5\u2212 with CD10+ groups may constitute clinically relevant subtypes","volume":"13","author":"Harada","year":"1999","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2020.05.003_bib7","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.3324\/haematol.12810","article-title":"De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients","volume":"93","author":"Yamaguchi","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2020.05.003_bib8","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1093\/annonc\/mdn392","article-title":"CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy","volume":"19","author":"Ennishi","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2020.05.003_bib9","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/hon.896","article-title":"The therapeutic effect of rituximab on CD5-positive and CD5-negative diffuse large B-cell lymphoma","volume":"28","author":"Hyo","year":"2010","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2020.05.003_bib10","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin\u2019s lymphoma","volume":"329","year":"1993","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2020.05.003_bib11","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/bjh.15001","article-title":"Bearing 19q13 aberration predicts poor prognosis in non-germinal centre type of CD5+DLBCL","volume":"183","author":"Mishima","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2020.05.003_bib12","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.autrev.2012.02.007","article-title":"CD5 expression promotes multiple intracellular signaling pathways in B lymphocyte","volume":"11","author":"Mageed","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.clml.2020.05.003_bib13","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0065-2776(08)60663-X","article-title":"The CD5 B cell","volume":"47","author":"Kipps","year":"1989","journal-title":"Adv Immunol"},{"key":"10.1016\/j.clml.2020.05.003_bib14","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1182\/blood.V91.4.1145","article-title":"De novo CD5+ diffuse large B-cell lymphomas express VH genes with somatic mutation","volume":"91","author":"Taniguchi","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.05.003_bib15","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1182\/blood-2005-02-0542","article-title":"Comparison of genome profiles for identification of distinct subgroups of diffuse large B-cell lymphoma","volume":"106","author":"Tagawa","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.05.003_bib16","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1200\/JCO.2005.03.4264","article-title":"BCL2 expression is a prognostic marker for the activated B-cell\u2013like type of diffuse large B-cell lymphoma","volume":"24","author":"Iqbal","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.05.003_bib17","doi-asserted-by":"crossref","first-page":"7070","DOI":"10.1182\/blood-2011-04-345256","article-title":"Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium","volume":"117","author":"Salles","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.05.003_bib18","doi-asserted-by":"crossref","first-page":"e0224247","DOI":"10.1371\/journal.pone.0224247","article-title":"Characteristics of CD5-positive diffuse large B cell lymphoma among Koreans: high incidence of BCL2 and MYC double-expressors","volume":"14","author":"Na","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2020.05.003_bib19","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/gcc.10298","article-title":"Analysis of chromosomal imbalances in de novo CD5-positive diffuse large\u2013B-cell lymphoma detected by comparative genomic hybridization","volume":"39","author":"Karnan","year":"2004","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.clml.2020.05.003_bib20","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1111\/j.1743-7563.2011.01432.x","article-title":"Cytogenetic analysis of de novo CD5-positive diffuse large B-cell lymphoma","volume":"7","author":"Kaneko","year":"2011","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.clml.2020.05.003_bib21","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/gcc.20127","article-title":"Cytogenetic features of de novo CD5-positive diffuse large B-cell lymphoma: chromosome aberrations affecting 8p21 and 11q13 constitute major subgroups with different overall survival","volume":"42","author":"Yoshioka","year":"2005","journal-title":"Genes Chromosomes Cancer"},{"key":"10.1016\/j.clml.2020.05.003_bib22","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1182\/blood-2002-06-1726","article-title":"Genetic analysis of de novo CD5+ diffuse large B-cell lymphomas suggests an origin from a somatically mutated CD5+ progenitor B cell","volume":"101","author":"Katzenberger","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.05.003_bib23","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1002\/ajh.24299","article-title":"De novo CD5+ diffuse large B-cell lymphoma: adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort","volume":"91","author":"Alinari","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2020.05.003_bib24","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1111\/j.1349-7006.2006.00267.x","article-title":"Expression profiling analysis of the CD5+ diffuse large B-cell lymphoma subgroup: development of a CD5 signature","volume":"97","author":"Suguro","year":"2006","journal-title":"Cancer Sci"},{"key":"10.1016\/j.clml.2020.05.003_bib25","first-page":"60","article-title":"Microarray reveals differences in both tumors and vascular specific gene expression in de novo CD5+ and CD5\u2212 diffuse large B-cell lymphomas","volume":"63","author":"Kobayashi","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2020.05.003_bib26","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/annonc\/mdh013","article-title":"Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large\u2013B-cell lymphoma: influence of rituximab","volume":"15","author":"Feugier","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2020.05.003_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13062-019-0255-8","article-title":"Differentially expressed tRFs in CD5 positive relapsed and and refractory diffuse large B cell lymphoma and the bioinformatic analysis for their potential clinical use","volume":"14","author":"Qu","year":"2019","journal-title":"Biol Direct"},{"key":"10.1016\/j.clml.2020.05.003_bib28","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.pathol.2017.09.006","article-title":"Diffuse large B-cell lymphoma","volume":"50","author":"Li","year":"2018","journal-title":"Pathology"},{"key":"10.1016\/j.clml.2020.05.003_bib29","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/PAS.0000000000000319","article-title":"Diffuse large B-cell lymphomas of immunoblastic type are a major reservoir for MYC-IGH translocations","volume":"39","author":"Horn","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.clml.2020.05.003_bib30","doi-asserted-by":"crossref","first-page":"2903","DOI":"10.1128\/MCB.19.4.2903","article-title":"CD5 negatively regulates the T-cell antigen receptor signal transduction pathway: involvement of SH2-containing phosphotyrosine phosphatase SHP-1","volume":"19","author":"Perez-Villar","year":"1999","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.clml.2020.05.003_bib31","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1034\/j.1600-065X.2000.00605.x","article-title":"Regulation of the phospholipase C-gamma2 pathway in B cells","volume":"176","author":"Kurosaki","year":"2000","journal-title":"Immunol Rev"},{"key":"10.1016\/j.clml.2020.05.003_bib32","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1038\/sj.onc.1202552","article-title":"Paired immunoglobulin-like receptor B (PIR-B) inhibits BCR-induced activation of Syk and Btk by SHP-1","volume":"18","author":"Maeda","year":"1999","journal-title":"Oncogene"},{"key":"10.1016\/j.clml.2020.05.003_bib33","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.4049\/jimmunol.165.3.1344","article-title":"Src homology region 2 (SH2) domain-containing phosphatase-1 dephosphorylates B cell linker protein\/SH2 domain leukocyte protein of 65 kDa and selectively regulates c-Jun NH2-terminal kinase activation in B cells","volume":"165","author":"Mizuno","year":"2000","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.clml.2020.05.003_bib34","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S0952-7915(96)80126-9","article-title":"Signals and susceptibility to programmed death in B cells","volume":"8","author":"Rothstein","year":"1996","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.clml.2020.05.003_bib35","doi-asserted-by":"crossref","first-page":"4537","DOI":"10.1182\/blood-2002-05-1525","article-title":"Human CD5 promotes B-cell survival through stimulation of autocrine IL-10 production","volume":"100","author":"Gary-Gouy","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.05.003_bib36","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/cmi.2016.42","article-title":"CD5 expression promotes IL-10 production through activation of the MAPK\/Erk pathway and upregulation of TRPC1 channels in B lymphocytes","volume":"15","author":"Garaud","year":"2018","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.clml.2020.05.003_bib37","doi-asserted-by":"crossref","first-page":"4835","DOI":"10.4049\/jimmunol.1003050","article-title":"CD5 Promotes IL-10 production in chronic lymphocytic leukemia B cells through STAT3 and NFAT2 activation","volume":"186","author":"Garaud","year":"2011","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.clml.2020.05.003_bib38","doi-asserted-by":"crossref","first-page":"4335","DOI":"10.4049\/jimmunol.179.7.4335","article-title":"Natural phosphorylation of CD5 in chronic lymphocytic leukemia B cells and analysis of CD5-regulated genes in a B cell line suggest a role for CD5 in malignant phenotype","volume":"179","author":"Gary-Gouy","year":"2007","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.clml.2020.05.003_bib39","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1189\/jlb.0803363","article-title":"Cyclin D2 controls B cell progenitor numbers","volume":"7 4","author":"Mohamedali","year":"2003","journal-title":"J\u00a0Leukoc Biol"},{"key":"10.1016\/j.clml.2020.05.003_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0115249","article-title":"Novel role for NFAT3 in ERK-mediated regulation of CXCR4","volume":"9","author":"Huang","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2020.05.003_bib41","doi-asserted-by":"crossref","first-page":"4322","DOI":"10.4049\/jimmunol.159.9.4322","article-title":"Cloning and analysis of the promoter region of CXCR4, a coreceptor for HIV-1 entry","volume":"159","author":"Moriuchi","year":"1997","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.clml.2020.05.003_bib42","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1038\/onc.2015.139","article-title":"CXCL12\/CXCR4: a symbiotic bridge linking cancer cells and their stromal neighbors in oncogenic communication networks","volume":"35","author":"Guo","year":"2016","journal-title":"Oncogene"},{"key":"10.1016\/j.clml.2020.05.003_bib43","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1746-1596-8-81","article-title":"De novo CD5-positive diffuse large B-cell lymphomas show high specificity for cyclin D2 expression","volume":"8","author":"Igawa","year":"2013","journal-title":"Diagn Pathol"},{"key":"10.1016\/j.clml.2020.05.003_bib44","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1007\/s12185-015-1812-2","article-title":"Gene expression profiling of diffuse large B-cell lymphomas supervised by CD5 expression","volume":"102","author":"Miyazaki","year":"2015","journal-title":"Int J Hematol"},{"key":"10.1016\/j.clml.2020.05.003_bib45","doi-asserted-by":"crossref","first-page":"12144","DOI":"10.1074\/jbc.M200102200","article-title":"Requirement for a hsp90 chaperone-dependent MEK1\/2-ERK pathway for B cell antigen receptor\u2013induced cyclin D2 expression in mature B lymphocytes","volume":"277","author":"Piatelli","year":"2002","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.clml.2020.05.003_bib46","doi-asserted-by":"crossref","first-page":"41040","DOI":"10.1074\/jbc.M105305200","article-title":"Vav is required for cyclin D2 induction and proliferation of mouse B lymphocytes activated via the antigen receptor","volume":"276","author":"Glassford","year":"2001","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.clml.2020.05.003_bib47","doi-asserted-by":"crossref","first-page":"232","DOI":"10.4049\/jimmunol.168.1.232","article-title":"CD5-negative regulation of b cell receptor signaling pathways originates from tyrosine residue Y429 outside an immunoreceptor tyrosine-based inhibitory motif","volume":"168","author":"Gary-Gouy","year":"2002","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.clml.2020.05.003_bib48","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1182\/blood-2011-10-388538","article-title":"Elevated serum IL-10 levels in diffuse large B-cell lymphoma: a mechanism of aberrant JAK2 activation","volume":"119","author":"Gupta","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.05.003_bib49","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1182\/blood-2018-03-841015","article-title":"B-cell receptor\u2013mediated NFATc1 activation induces IL-10\/STAT3\/PD-L1 signaling in diffuse large B-cell lymphoma","volume":"132","author":"Li","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.05.003_bib50","doi-asserted-by":"crossref","first-page":"30707","DOI":"10.1074\/jbc.M202460200","article-title":"Peritoneal CD5+ B-1 cells have signaling properties similar to tolerant B cells","volume":"277","author":"Wong","year":"2002","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.clml.2020.05.003_bib51","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1074\/jbc.275.1.548","article-title":"The pseudo-immunoreceptor tyrosine-based activation motif of CD5 mediates its inhibitory action on B-cell receptor signaling","volume":"275","author":"Gary-Gouy","year":"2000","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.clml.2020.05.003_bib52","doi-asserted-by":"crossref","first-page":"3749","DOI":"10.4049\/jimmunol.174.6.3749","article-title":"B\u00a0cell response to surface IgM cross-linking identifies different prognostic groups of B-chronic lymphocytic leukemia patients","volume":"174","author":"N\u00e9dellec","year":"2005","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.clml.2020.05.003_bib53","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.4049\/jimmunol.178.5.2623","article-title":"The JAK-STAT signaling pathway: input and output integration","volume":"178","author":"Murray","year":"2007","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.clml.2020.05.003_bib54","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/S1357-2725(99)00069-2","article-title":"Role of nuclear factor of activated T cells (NFAT) in the expression of interleukin-5 and other cytokines involved in the regulation of hemopoetic cells","volume":"31","author":"De Boer","year":"1999","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.clml.2020.05.003_bib55","doi-asserted-by":"crossref","first-page":"81","DOI":"10.3109\/10428199409051655","article-title":"Expression of Bcl-2 protein and Bcl-2 mRNA in normal and neoplastic lymphoid tissues","volume":"13","author":"Akagi","year":"1994","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2020.05.003_bib56","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1046\/j.1365-2141.1996.d01-1856.x","article-title":"In leukaemic CD5+ B cells the expression of BCL-2 gene family is shifted toward protection from apoptosis","volume":"94","author":"Gottardi","year":"1996","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2020.05.003_bib57","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1007\/s00277-014-2035-y","article-title":"Tandem triplication of the BCL2 gene in CD5-positive intravascular large B cell lymphoma with bone marrow involvement","volume":"93","author":"Yamamoto","year":"2014","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2020.05.003_bib58","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/0092-8674(95)90385-2","article-title":"The retinoblastoma protein and cell cycle control","volume":"81","author":"Weinberg","year":"1995","journal-title":"Cell"},{"key":"10.1016\/j.clml.2020.05.003_bib59","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1056\/NEJMoa032520","article-title":"Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes","volume":"350","author":"Lossos","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2020.05.003_bib60","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/nrc1388","article-title":"Cancer and the chemokine network","volume":"4","author":"Balkwill","year":"2004","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.clml.2020.05.003_bib61","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/978-0-387-72009-8_9","article-title":"The chemokine CXCL12 and regulation of HSC and B lymphocyte development in the bone marrow niche","volume":"602","author":"Nagasawa","year":"2007","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.clml.2020.05.003_bib62","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/path.4446","article-title":"CXCR4 expression enhances diffuse large B cell lymphoma dissemination and decreases patient survival","volume":"235","author":"Moreno","year":"2015","journal-title":"J\u00a0Pathol"},{"key":"10.1016\/j.clml.2020.05.003_bib63","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1080\/10428194.2017.1379077","article-title":"Clinical significance of chemokine receptor CXCR4 and mammalian target of rapamycin (mTOR) expression in patients with diffuse large B-cell lymphoma","volume":"59","author":"Xu","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2020.05.003_bib64","doi-asserted-by":"crossref","first-page":"5597","DOI":"10.18632\/oncotarget.3343","article-title":"Dysregulated CXCR4 expression promotes lymphoma cell survival and independently predicts disease progression in germinal center B-cell\u2013like diffuse large B-cell lymphoma","volume":"6","author":"Chen","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.clml.2020.05.003_bib65","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1196\/annals.1329.021","article-title":"CXCR4 activation induces epidermal growth factor receptor transactivation in an ovarian cancer cell line","volume":"1030","author":"Porcile","year":"2004","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.clml.2020.05.003_bib66","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.3389\/fimmu.2017.01773","article-title":"The CXCR4-STAT3-IL-10 pathway controls the immunoregulatory function of chronic lymphocytic leukemia and is modulated by lenalidomide","volume":"8","author":"Shaim","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.clml.2020.05.003_bib67","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.1038\/onc.2014.403","article-title":"The tumor microenvironment shapes hallmarks of mature B-cell malignancies","volume":"34","author":"Shain","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.clml.2020.05.003_bib68","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1365-2141.2006.06438.x","article-title":"Dose-adjusted EPOCH plus rituximab is an effective regimen in patient with poor-prognostic untreated diffuse large B-cell lymphoma: results from a prospective observational study","volume":"136","author":"Garcia-Suarez","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2020.05.003_bib69","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/ejh.12847","article-title":"Prognostic impact of CD5 expression in diffuse large B-cell lymphoma in patients treated with rituximab-EPOCH","volume":"98","author":"Thakral","year":"2017","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2020.05.003_bib70","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1080\/16078454.2019.1614289","article-title":"Clinicopathologic significance and therapeutic implication of de novo CD5+ diffuse large B-cell lymphoma","volume":"24","author":"Tang","year":"2019","journal-title":"Hematology"},{"key":"10.1016\/j.clml.2020.05.003_bib71","doi-asserted-by":"crossref","first-page":"4284","DOI":"10.1182\/blood-2003-02-0542","article-title":"Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma","volume":"102","author":"Tilly","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.05.003_bib72","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1016\/S0140-6736(11)61040-4","article-title":"Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial","volume":"378","author":"R\u00e9cher","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2020.05.003_bib73","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1200\/JCO.2003.99.053","article-title":"International Collaborative Group Against Primary CNS Lymphomas","volume":"21","author":"Ferreri","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.05.003_bib74","doi-asserted-by":"crossref","first-page":"79","DOI":"10.3960\/jslrt.56.79","article-title":"Treatment of diffuse large B-cell lymphoma","volume":"56","author":"Miyazaki","year":"2016","journal-title":"J\u00a0Clin Exp Hematop"},{"key":"10.1016\/j.clml.2020.05.003_bib75","doi-asserted-by":"crossref","first-page":"7561","DOI":"10.1200\/JCO.2018.36.15_suppl.7561","article-title":"Dose-adjusted (DA)-EPOCH-R with high-dose methotrexate (HD-MTX) for newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma (CD5+ DLBCL): primary analysis of PEARL5 study","volume":"36","author":"Miyazaki","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.05.003_bib76","first-page":"1038","article-title":"CD5-positive DLBCL: molecular basis and treatment strategies","volume":"56","author":"Miyazaki","year":"2015","journal-title":"J-Stage"},{"key":"10.1016\/j.clml.2020.05.003_bib77","first-page":"33","article-title":"Prognostic analysis of CD5 expression in double-hit diffuse large B-cell lymphoma and effectiveness comparison in patients treated with dose-adjusted EPOCH plus rituximab\/R-CHOP regimens","volume":"9","author":"Zhang","year":"2019","journal-title":"Blood Lymphat Cancer"},{"key":"10.1016\/j.clml.2020.05.003_bib78","first-page":"722","article-title":"[Rituximab plus autologous hemotopoietic stem cell transplantation for the treatment of CD5 positive diffuse large B cell lymphoma with autoimmune hemolytic anemia]","volume":"24","author":"Huang","year":"2016","journal-title":"Zhongguo Shi Yan Xue Ye Xue Za Zhi"},{"key":"10.1016\/j.clml.2020.05.003_bib79","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1200\/JCO.2014.55.5714","article-title":"Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma: a phase II study","volume":"33","author":"Nowakowski","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.05.003_bib80","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1080\/15384047.2018.1449609","article-title":"Lenalidomide combined with R-GDP in a patient with refractory CD5-positive diffuse large B-cell lymphoma: a promising response and review","volume":"19","author":"Zhang","year":"2018","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.clml.2020.05.003_bib81","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1182\/blood.2018891598","article-title":"Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed\/refractory non\u2013germinal center B-cell\u2013like DLBCL","volume":"134","author":"Goy","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.05.003_bib82","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1016\/S1470-2045(14)70311-0","article-title":"Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomized, phase 1b study","volume":"15","author":"Younes","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2020.05.003_bib83","first-page":"1093","article-title":"Mechanism of action of EBV, Bcl-2, p53, c-Myc and Rb in non-Hodgkin\u2019s lymphoma","volume":"20","author":"Song","year":"2016","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.clml.2020.05.003_bib84","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2020.05.003_bib85","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/blood-2016-12-759621","article-title":"BCL2 expression in DLBCL: reappraisal of immunohistochemistry with new criteria for therapeutic biomarker evaluation","volume":"130","author":"Tsuyama","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.05.003_bib86","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1158\/1535-7163.MCT-16-0555","article-title":"Combination of ibrutinib and ABT-199 in diffuse large B-cell lymphoma and follicular lymphoma","volume":"16","author":"Kuo","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.clml.2020.05.003_bib87","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1182\/blood-2018-11-880526","article-title":"Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial","volume":"133","author":"Zelenetz","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.05.003_bib88","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.1158\/0008-5472.CAN-17-0082","article-title":"Venetoclax synergizes with radiotherapy for treatment of B-cell lymphomas","volume":"77","author":"O\u2019Steen","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.clml.2020.05.003_bib89","doi-asserted-by":"crossref","first-page":"778","DOI":"10.3324\/haematol.2017.180505","article-title":"Pharmacological modulation of CXCR4 cooperates with BET bromodomain inhibition in diffuse large B-cell lymphoma","volume":"104","author":"Recasens-Zorzo","year":"2019","journal-title":"Heamatologica"},{"key":"10.1016\/j.clml.2020.05.003_bib90","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1182\/blood-2005-08-3182","article-title":"CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment","volume":"107","author":"Burger","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.05.003_bib91","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-13-0855","article-title":"PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies","volume":"19","author":"Chen","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clml.2020.05.003_bib92","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/pin.12742","article-title":"Immune evasion-related extranodal large B-cell lymphoma: a report of six patients with neoplastic PD-L1\u2013positive extranodal diffuse large B-cell lymphoma","volume":"69","author":"Suzuki","year":"2019","journal-title":"Pathol Int"},{"key":"10.1016\/j.clml.2020.05.003_bib93","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/bjh.16494","article-title":"Pembrolizumab with R-CHOP in previously untreated diffuse large B-cell lymphoma: potential for biomarker driven therapy","volume":"189","author":"Smith","year":"2020","journal-title":"Br J Haematol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020302196?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020302196?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:36:02Z","timestamp":1761870962000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265020302196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":93,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S2152265020302196"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2020.05.003","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"De Novo CD5+ Diffuse Large B-Cell Lymphoma: Biology, Mechanism, and Treatment Advances","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2020.05.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}